CSIMarket Company Name, Ticker, Competitors, else..
 
Panbela Therapeutics Inc   (PBLA)
 

Panbela Therapeutics Inc's Suppliers Performance

PBLA's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
PBLA Costs vs Sales of Suppliers Growth

• More on PBLA Suppliers






Panbela Therapeutics Inc's Comment on Supply Chain


The company does not own or operate manufacturing facilities and relies on third-party manufacturers for the production of product candidates used in preclinical and clinical testing, as well as potential commercial manufacture. It plans to engage third-party manufacturers through supply agreements to obtain additional clinical supply of ivospemin. The company has identified and qualified manufacturers for the active pharmaceutical ingredient and fill-and-finish services for its initial product candidate prior to NDA submission to the FDA and intends to maintain this approach for other candidates. The company holds a Standard Exclusive License Agreement with UFRF, granting exclusive rights to proprietary technology covered by certain patents. Amendments to this agreement have eliminated minimum royalty and milestone payments and established royalty payment periods. UFRF may terminate the license under specific conditions, including if the first commercial sale is not made by December 31, 2025. Pharmaceutical products are subject to extensive FDA regulation encompassing all stages from research through marketing. Non-compliance with these regulations may result in various sanctions.

Panbela Therapeutics Inc's Comment on Supply Chain


The company does not own or operate manufacturing facilities and relies on third-party manufacturers for the production of product candidates used in preclinical and clinical testing, as well as potential commercial manufacture. It plans to engage third-party manufacturers through supply agreements to obtain additional clinical supply of ivospemin. The company has identified and qualified manufacturers for the active pharmaceutical ingredient and fill-and-finish services for its initial product candidate prior to NDA submission to the FDA and intends to maintain this approach for other candidates. The company holds a Standard Exclusive License Agreement with UFRF, granting exclusive rights to proprietary technology covered by certain patents. Amendments to this agreement have eliminated minimum royalty and milestone payments and established royalty payment periods. UFRF may terminate the license under specific conditions, including if the first commercial sale is not made by December 31, 2025. Pharmaceutical products are subject to extensive FDA regulation encompassing all stages from research through marketing. Non-compliance with these regulations may result in various sanctions.







PBLA's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Panbela Therapeutics Inc 0.05 0.00 -27.92 26
SUBTOTAL 0.00 0.00 0.00 -


Sources: Panbela Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Panbela Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.